Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > #ASCO22 Annual Meeting - June 3-7, 2022

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston May 26, 2022 8:04pm

164 Views

Post# 34710773

RE:#ASCO22 Annual Meeting - June 3-7, 2022

Another big pharma that we could compare against their innovative oncology pipeline, to see where we stand and what they mean about "innovation":

SANOFI Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting

Safety and efficacy data for SAR439459, a transforming growth factor beta (TGF-β) inhibitor*

Abstract 2524: Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"